ADIPOQ and Insulin resistance: The glucose‐lowering effects of thiazolidinediones are due to increased disposal of glucose into adipose tissues along with increased expression of insulin sensitizing factors, such as adiponectin (Hirose et al., 2002), and decreased expression of proteins that promote insulin resistance such as FGF‐21 (Li et al., 2009).